Financials Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
1,100 USD +1.83% Intraday chart for Regeneron Pharmaceuticals, Inc. +6.36% +25.25%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 41,049 50,990 66,029 77,057 93,403 116,545 - -
Enterprise Value (EV) 1 35,291 50,098 56,196 77,057 84,542 107,786 102,015 95,449
P/E ratio 20.3 x 15.8 x 8.77 x 18.9 x 25.3 x 32 x 28.7 x 23.8 x
Yield - - - - - - - -
Capitalization / Revenue 5.22 x 6 x 4.11 x 6.33 x 7.12 x 8.43 x 7.79 x 7.3 x
EV / Revenue 4.49 x 5.9 x 3.5 x 6.33 x 6.45 x 7.8 x 6.82 x 5.98 x
EV / EBITDA 10.3 x 11.8 x 5.71 x 12.7 x 15.2 x 19.5 x 17.2 x 14.5 x
EV / FCF 17.6 x 25 x 8.61 x 17.4 x 21.8 x 20.6 x 20.2 x 16.9 x
FCF Yield 5.67% 4% 11.6% 5.74% 4.58% 4.86% 4.94% 5.93%
Price to Book 3.7 x 4.71 x 3.56 x 3.41 x 3.64 x 4.03 x 3.47 x 2.99 x
Nbr of stocks (in thousands) 109,323 105,544 104,556 106,802 106,347 107,886 - -
Reference price 2 375.5 483.1 631.5 721.5 878.3 1,080 1,080 1,080
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,863 8,497 16,072 12,173 13,117 13,820 14,954 15,973
EBITDA 1 3,420 4,244 9,835 6,060 5,547 5,528 5,931 6,590
EBIT 1 2,210 3,577 8,947 5,719 5,126 5,120 5,583 6,208
Operating Margin 28.1% 42.09% 55.67% 46.98% 39.08% 37.05% 37.34% 38.87%
Earnings before Tax (EBT) 1 2,429 3,810 9,326 4,859 4,199 4,242 4,839 5,444
Net income 1 2,116 3,513 8,075 4,338 3,954 4,041 4,438 5,166
Net margin 26.91% 41.35% 50.25% 35.64% 30.14% 29.24% 29.68% 32.34%
EPS 2 18.46 30.52 71.97 38.22 34.77 33.80 37.65 45.41
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 5,235 5,043 5,662
FCF margin 25.44% 23.58% 40.63% 36.35% 29.54% 37.88% 33.73% 35.45%
FCF Conversion (EBITDA) 58.5% 47.2% 66.39% 73.01% 69.86% 94.7% 85.04% 85.92%
FCF Conversion (Net income) 94.55% 57.03% 80.86% 101.99% 98.02% 129.55% 113.63% 109.61%
Dividend per Share 2 - - - - - - - -
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,952 2,965 2,857 2,936 3,414 3,162 3,158 3,363 3,434 3,145 3,369 3,555 3,722 3,566 3,617
EBITDA 1 2,903 1,558 1,344 1,488 1,637 1,315 1,351 1,488 1,395 1,142 1,311 1,496 1,613 1,193 1,285
EBIT 1 2,640 1,483 1,285 1,413 1,537 1,215 1,248 1,382 1,282 1,028 1,213 1,361 1,425 1,312 1,369
Operating Margin 53.31% 50.03% 44.99% 48.12% 45.02% 38.43% 39.51% 41.11% 37.33% 32.68% 36.01% 38.3% 38.29% 36.78% 37.85%
Earnings before Tax (EBT) 1 2,503 1,061 963.2 1,510 1,325 858 1,083 1,111 1,148 700.7 1,125 1,138 1,235 - -
Net income 1 2,229 973.5 852.1 1,316 1,197 817.8 968.4 1,008 1,160 722 1,033 1,154 1,187 1,195 1,198
Net margin 45.01% 32.83% 29.82% 44.81% 35.06% 25.86% 30.66% 29.97% 33.77% 22.96% 30.66% 32.47% 31.88% 33.52% 33.12%
EPS 2 19.69 8.610 7.470 11.66 10.50 7.170 8.500 8.890 10.19 6.270 8.155 9.500 9.783 9.330 9.327
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 04/02/22 04/05/22 03/08/22 03/11/22 03/02/23 04/05/23 03/08/23 02/11/23 02/02/24 02/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,757 891 9,833 - 8,862 8,760 14,530 21,096
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 5,235 5,043 5,662
ROE (net income / shareholders' equity) 28.5% 33.2% 54.2% 24.9% 20.7% 18.2% 16.9% 16.2%
ROA (Net income/ Total Assets) 15.9% 22% 37.9% 18.9% 16.2% 11.8% 11.4% 12.1%
Assets 1 13,270 15,984 21,299 22,956 24,412 34,234 38,814 42,533
Book Value Per Share 2 102.0 102.0 178.0 212.0 241.0 268.0 311.0 361.0
Cash Flow per Share 2 21.20 22.70 63.10 44.20 40.40 45.80 47.40 48.60
Capex 1 430 615 552 590 719 836 744 760
Capex / Sales 5.46% 7.23% 3.43% 4.85% 5.48% 6.05% 4.97% 4.76%
Announcement Date 06/02/20 05/02/21 04/02/22 03/02/23 02/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,080 USD
Average target price
1,063 USD
Spread / Average Target
-1.59%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Financials Regeneron Pharmaceuticals, Inc.